Premium
The current status in hematopoietic stem cell mobilization
Author(s) -
Civriz Bozdag Sinem,
Tekgunduz Emre,
Altuntas Fevzi
Publication year - 2015
Publication title -
journal of clinical apheresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.697
H-Index - 46
eISSN - 1098-1101
pISSN - 0733-2459
DOI - 10.1002/jca.21374
Subject(s) - plerixafor , mobilization , medicine , cxcr4 , apheresis , stem cell , surgery , platelet , inflammation , genetics , chemokine , archaeology , biology , history
Hemotopoietic stem cell mobilization with cytokines alone, has still been widely accepted as the initial attempt for stem cell mobilization. Chemotherapy based mobilization can be preferred as first choice in high risk patients or for remobilization. But mobilization failure still remains to be a problem in one third of patients. Salvage mobilization strategies have been composed to give one more chance to ‘poor mobilizers’. Synergistic effect of a reversible inhibitor of CXCR4, plerixafor, with G‐CSF has opened a new era for these patients. Preemptive approach in predicted poor mobilizers, immediate salvage approach for patients with suboptimal mobilization or remobilization approach of plerixafor in failed mobilizers have all been demonstrated convincing results in various studies. Alternative CXCR4 inhibitors, VLA4 inhibitors, bortezomib, parathormone have also been emerged as novel agents for mobilization failure. J. Clin. Apheresis 30:273–280, 2015. © 2015 Wiley Periodicals, Inc.